D.C. Circuit Confirms Drug Makers Need HHS Approval for 340B Rebate Models
- July 24, 2026
- Written by AHLA Legal Staff
Drug manufacturers may not unilaterally shift to a rebate model for providing discounts under the 340B program without the Department of Health and Human Services Secretary’s approval, the D.C. Circuit held July 21.
ARTICLE TAGS
You must be logged in to access this content.